Allergy Therapeutics chill worsens.
Investors Chronicle - magazine and web content, March, 2008
TIP UPDATE: Share price in the doldrums as stand-off with FDA shows no sign of easing. Richard Hemming
Allergy Therapeutics' shares fell over 15 per cent after management said it had no idea when the US regulator's suspension of clinical trials for its grass allergies vaccine would end.
The shares have more than halved since the US Food and Drug Administration (FDA) first called a halt to trials in July of Allergy's vaccine adjuvant, Pollinex Quattro. A patient in the trial suffered rare neurological side effects, but has since recovered. Chief executive Keith Carter says that the FDA is dragging its feet on approving all vaccine adjuvants - an adjuvant is a catalyst that helps improve the effectiveness of a vaccine.
Click here for a...
Most Recent Business Articles
- Your feedback
- Why fly solo when an executive assistant can accelerate your CLNC® business?
- The CLNC® mentors held the key to my first case and to my CLNC® success
- Atlanta CLNC® 6-day certification seminar photo gallery—plus sign up today for spring 2009 to save $100.00
- Announcing the 2009 NACLNC® conference keynote speaker, Stedman Graham: move like a maverick for breakaway CLNC® success at the 2009 NACLNC® conference
Most Recent Business Publications
Most Popular Business Articles
- Using object-oriented analysis and design over traditional structured analysis and design
- Big Fish Games Migrates Upstream to Fisher Plaza; High Growth Online Gaming Firm Vaults Fisher Plaza Occupancy Rate Above 90%
- Top of the line: some of the world's most well-respected doctors practice in South Florida. A guide to choosing the best physician specialists - Top Doctors in South Florida
- BEHR Paints Introduces a Colorful New Way to Paint and Prime All in One with BEHR Premium Plus Ultra™ Interior
- Sand filter basics: high-rate sand filters can be confusing for those new to the business. Understanding valve modes is the key
